Citadel Advisors
ABVX

Citadel Advisors’s Abivax ABVX Stock Holding History

Citadel Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192M Buy
1,438,352
+894,014
+164% +$101M 0.02% 578
2026
Q1 		$60.6M Sell
544,338
-19,409
-3% -$2.3M 0.01% 1182
2025
Q4 		$76M Sell
563,747
-118,038
-17% -$12.9M 0.01% 1058
2025
Q3 		$57.9M Sell
681,785
-570,472
-46% -$35M 0.01% 1244
2025
Q2 		$9.58M Sell
1,252,257
-121,603
-9% -$793K ﹤0.01% 3087
2025
Q1 		$8.59M Buy
1,373,860
+518,184
+61% +$3.51M ﹤0.01% 3060
2024
Q4 		$6.26M Buy
855,676
+389,247
+83% +$3.58M ﹤0.01% 3612
2024
Q3 		$5.37M Buy
466,429
+11,669
+3% +$140K ﹤0.01% 3830
2024
Q2 		$6.01M Sell
454,760
-96,750
-18% -$1.38M ﹤0.01% 3462
2024
Q1 		$7.89M Sell
551,510
-181,357
-25% -$2.34M ﹤0.01% 3267
2023
Q4 		$7.84M Buy
+732,867
New +$7.47M ﹤0.01% 3163

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Citadel Advisors's ABVX Position: Q2 2026 in Review

Citadel Advisors increased its Abivax (ABVX) stake by 164% in Q2 2026, buying an estimated $101M and bringing the position to 1,438,352 shares worth $192M. The position accounts for 0.02% of the portfolio, ranked #578.

Citadel Advisors first reported a position in ABVX in Q4 2023 and has held it in 11 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Citadel Advisors held 1,438,352 shares of Abivax worth $192M as of Q2 2026.
  • Citadel Advisors bought 894,014 Abivax shares in Q2 2026, an estimated $101M.
  • Abivax made up 0.02% of Citadel Advisors's portfolio in Q2 2026, its #578 holding.
  • Citadel Advisors first reported a position in Abivax in Q4 2023 and has held it in 11 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.